Jounce Therapeutics is dedicated to transforming the treatment of cancer. The company is discovering and developing first-in-class cancer immunotherapies designed to harness the immune system to seek out and attack cancerous cells and tumors. Jounce's proprietary product engine is driving this transformational approach, which has the potential to drive significantly more durable responses to treatment, extending and improving patients' quality of life. Founded by world leaders in immunobiology, cancer biology and clinical and translational medicine, Jounce Therapeutics was launched in 2013.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 02/14/13 | $47,000,000 | Series A | ||
| 04/23/15 | $56,000,000 | Series B |
Casdin Capital Cormorant Asset Management Foresite Capital Nextech Invest Omega Funds Pharmstandard International Redmile Group Wellington Management Company | undisclosed |
